



FOR IMMEDIATE RELEASE

**ChemGenex to Present at Rodman & Renshaw Global Investment
Conference in the U.S.**

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (September 9th, 2009) – ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that Greg Collier, PhD, Chief Executive Officer and Managing Director will present a company update at the Rodman and Renshaw 11th Annual Healthcare Conference at the New York Palace Hotel on Wednesday, 9 September 2009 at 4:55 p.m. Eastern Time in the U.S. (Thursday, 10 September 2009 at 6:55 a.m. in Eastern Australia).

The presentation will be webcast live and will also be available on the Company's website (<http://www.chemgenex.com>).

About ChemGenex Pharmaceuticals Limited (<http://www.chemgenex.com>)

ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The company is developing its lead product candidate OMAPRO™ (formerly omacetaxine) for the treatment of patients with Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). A New Drug Application has been submitted to the U.S. Food and Drug Administration for CML patients with the Bcr-Abl T315I mutation. The corporate strategy for ChemGenex is to commercialize OMAPRO™ independently in North America and to establish commercial partnerships in the rest of the world. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS". For additional information on ChemGenex Pharmaceuticals, please visit the company's website at <http://www.chemgenex.com>.

Details on the clinical trials can be accessed from the following websites;

<http://clinicaltrials.gov/ct2/show/NCT00375219?term=homoharringtonine&rank=9> and
<http://www.tkiresistantcmltrials.com>

Contacts

ChemGenex Information

Dr. Greg Collier
CEO and Managing Director
Cell (Australia): +61 419 897501
Cell (USA): +1 650 200 8145
Email: gcollier@chemgenex.com

Investor Relations – Australia

Rebecca Wilson
Buchan Consulting
Tel: +61 (0)3 9866 4722
Cell: + 61 (0)417 382 391
Email: rwilson@bcg.com.au

Investor Relations – USA

Remy Bernarda
Blueprint Life Science Group
Tel: +1 415 375 3340 x 2022
Cell: +1 415 203 6386
Email:
rbernarda@bplifescience.com